Haleon plc has experienced considerable shifts in
shareholdings and capital.
Pfizer, initially a significant stakeholder, has progressively sold off its equity, reducing its stake to 7.3%. Through multiple rounds of share sales, Pfizer has netted a considerable profit. Concurrently,
Haleon has actioned a series of share buyback programs, bolstering its stockholder value. Its stock is seen as an attractive buy by analysts with a $10.95 consensus price target, although the firm faced a downgrade from
Bernstein due to growth concerns. Its financial performance has been impacted by a stronger pound leading it to miss Q3 forecasts. However,
Morgan Stanley cites top-line growth for favoring
Haleon's stock. Institutional investors, such as BlackRock, have increased their stake in Haleon. Internally,
Haleon has refreshed its executive share options and witnessed various transactions. The company also outlined plans to invest $54 million into a US R&D center to spur product innovation. It's worth mentioning that
Haleon dominates its share ownership with 54% held by institutional owners.
Haleon Stocks News Analytics from Mon, 18 Mar 2024 07:00:00 GMT to Sat, 08 Feb 2025 06:11:02 GMT -
Rating 4
- Innovation 7
- Information 6
- Rumor 0
